JPH07501538A - 医薬組成物 - Google Patents

医薬組成物

Info

Publication number: JPH07501538A
Authority: JP; Japan
Prior art keywords: pharmaceutically acceptable; compound; acceptable salt; oxopiperidin; dimethyl
Prior art date: 1991-12-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP5509963A

Other languages

English (en)

Japanese (ja)

Inventor

アーチ，ジョナサン・ロバート・サンダース

ボウリング，ニコラス・エドワード

Original Assignee

スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-05

Filing date

1992-12-01

Publication date

1995-02-16

1991-12-05 Priority claimed from GB919125862A external-priority patent/GB9125862D0/en

1992-06-19 Priority claimed from GB929213042A external-priority patent/GB9213042D0/en

1992-12-01 Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

1995-02-16 Publication of JPH07501538A publication Critical patent/JPH07501538A/ja

Status Pending legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 18
150000001875 compounds Chemical class 0.000 claims description 41
239000000203 mixture Substances 0.000 claims description 27
150000003839 salts Chemical class 0.000 claims description 21
239000012453 solvate Substances 0.000 claims description 15
239000003937 drug carrier Substances 0.000 claims description 10
238000000034 method Methods 0.000 claims description 10
239000000843 powder Substances 0.000 claims description 7
208000000884 Airway Obstruction Diseases 0.000 claims description 5
239000000443 aerosol Substances 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
230000002441 reversible effect Effects 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 3
239000006199 nebulizer Substances 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 2
210000002345 respiratory system Anatomy 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims 1
229940127557 pharmaceutical product Drugs 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
208000024891 symptom Diseases 0.000 claims 1
239000003981 vehicle Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
239000003826 tablet Substances 0.000 description 5
208000006673 asthma Diseases 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229940055577 oleyl alcohol Drugs 0.000 description 2
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
-1 shi7tin Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
241000220479 Acacia Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
241000218671 Ephedra Species 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
150000001562 benzopyrans Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229960001317 isoprenaline Drugs 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
229960002329 methacholine Drugs 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
238000005507 spraying Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP5509963A 1991-12-05 1992-12-01 医薬組成物 Pending JPH07501538A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB919125862A GB9125862D0 (en)	1991-12-05	1991-12-05	Pharmaceutical composition
GB9125862.4		1991-12-05
GB929213042A GB9213042D0 (en)	1992-06-19	1992-06-19	Pharmaceutical composition
GB9213042.6		1992-06-19
PCT/GB1992/002234 WO1993010757A1 (fr)	1991-12-05	1992-12-01	Composition pharmaceutique

Publications (1)

Publication Number	Publication Date
JPH07501538A true JPH07501538A (ja)	1995-02-16

Family

ID=26299960

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP5509963A Pending JPH07501538A (ja)	1991-12-05	1992-12-01	医薬組成物

Country Status (15)

Country	Link
EP (1)	EP0615437A1 (fr)
JP (1)	JPH07501538A (fr)
AP (1)	AP382A (fr)
AU (1)	AU2954292A (fr)
BR (1)	BR9206845A (fr)
CA (1)	CA2125156A1 (fr)
CZ (1)	CZ136394A3 (fr)
HU (1)	HUT70745A (fr)
IL (1)	IL103952A0 (fr)
MA (1)	MA22731A1 (fr)
MX (1)	MX9206975A (fr)
RU (1)	RU94030464A (fr)
SI (1)	SI9200365A (fr)
SK (1)	SK65794A3 (fr)
WO (1)	WO1993010757A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0076075B1 (fr) *	1981-09-25	1986-11-20	Beecham Group Plc	Dérivés de benzopyranes pharmacologiquement actifs
DE3368629D1 (en) *	1982-04-28	1987-02-05	Beecham Group Plc	Novel chromenes and chromans
IL86798A (en) *	1987-06-23	1992-12-01	Sanofi Sa	2,2-dimethylchroman-3-ol derivatives, their preparation and pharmaceutical compositions containing them
ATE120459T1 (de) *	1988-12-13	1995-04-15	Beecham Group Plc	Benzopyran und verwandte verbindungen.

1992
- 1992-12-01 EP EP92923956A patent/EP0615437A1/fr not_active Withdrawn
- 1992-12-01 BR BR9206845A patent/BR9206845A/pt not_active Application Discontinuation
- 1992-12-01 RU RU94030464/14A patent/RU94030464A/ru unknown
- 1992-12-01 WO PCT/GB1992/002234 patent/WO1993010757A1/fr not_active Ceased
- 1992-12-01 CZ CZ941363A patent/CZ136394A3/cs unknown
- 1992-12-01 AU AU29542/92A patent/AU2954292A/en not_active Abandoned
- 1992-12-01 CA CA002125156A patent/CA2125156A1/fr not_active Abandoned
- 1992-12-01 JP JP5509963A patent/JPH07501538A/ja active Pending
- 1992-12-01 HU HU9401681A patent/HUT70745A/hu unknown
- 1992-12-01 SK SK657-94A patent/SK65794A3/sk unknown
- 1992-12-03 MA MA23021A patent/MA22731A1/fr unknown
- 1992-12-03 IL IL103952A patent/IL103952A0/xx unknown
- 1992-12-03 MX MX9206975A patent/MX9206975A/es unknown
- 1992-12-04 AP APAP/P/1992/000454A patent/AP382A/en active
- 1992-12-04 SI SI19929200365A patent/SI9200365A/sl unknown

Also Published As

Publication number	Publication date
AP382A (en)	1995-05-03
BR9206845A (pt)	1996-01-02
IL103952A0 (en)	1993-05-13
AP9200454A0 (en)	1993-01-31
HUT70745A (en)	1995-10-30
CA2125156A1 (fr)	1993-06-10
MA22731A1 (fr)	1993-07-01
HU9401681D0 (en)	1994-09-28
CZ136394A3 (en)	1995-02-15
RU94030464A (ru)	1996-04-27
MX9206975A (es)	1993-06-01
AU2954292A (en)	1993-06-28
EP0615437A1 (fr)	1994-09-21
SK65794A3 (en)	1995-02-08
SI9200365A (en)	1993-06-30
WO1993010757A1 (fr)	1993-06-10

Publication	Publication Date	Title
EP0742715B1 (fr)	1999-04-07	Compositions liquides buvables contenant un resinate de paroxetine
EP0991646B1 (fr)	2002-04-24	Itraconazole possedant une meilleure solubilite, procede de preparation de ce dernier et composition pharmaceutique pour administration orale comprenant cet itraconazole
US20040147605A1 (en)	2004-07-29	Drug preparations
JP2002509883A (ja)	2002-04-02	フマル酸アルキル水素エステルからなる乾癬、乾癬性関節炎、神経皮膚炎および限局性回腸炎クローン病の治療剤
JPH092944A (ja)	1997-01-07	眼用医薬組成物及びその投与方法
KR100525275B1 (ko)	2005-11-02	시알산 유도체를 함유하는 고체분산체
JPH09505818A (ja)	1997-06-10	薬／ポリマー複合体含有の風味をマスクした組成物
JP2001518923A (ja)	2001-10-16	鼻腔用メラトニン組成物
JPWO1999052931A1 (ja)	2002-10-29	シアル酸誘導体を含む固体分散体
JPH04360833A (ja)	1992-12-14	１，４−ジヒドロピリジン誘導体を含有する製剤
US20030064034A1 (en)	2003-04-03	Use of compounds in a dry powder inhaler
EP0535237A1 (fr)	1993-04-07	Composition soulageant les irritations cutanees et preparation pour administration percutanee a usage externe contenant ladite composition
IE60930B1 (en)	1994-09-07	Synergistic combination of azelastine and theophylline or azelastine and beta-mimetics
CN1117565C (zh)	2003-08-13	西兰塞特隆的抗外消旋的稳定的药物制剂
TWI286072B (en)	2007-09-01	Sleeping medicine formed by coating solid
JPH07501538A (ja)	1995-02-16	医薬組成物
JPH08325142A (ja)	1996-12-10	ヨウ化イソプロパミド含有製剤
JPH0797330A (ja)	1995-04-11	経口コレステロール低下剤
WO2007091059A1 (fr)	2007-08-16	Préparation et composition d'une forme posologique solide contenant du tacrolimus et/ou du sirolimus
JPS61268623A (ja)	1986-11-28	抗喘息剤
JPH06506706A (ja)	1994-07-28	ベンゾフルメトールを含有する抗マラリア性の相乗作用組成物
US20090111831A1 (en)	2009-04-30	Pharmaceutical compositions
KR100981750B1 (ko)	2010-09-10	분무-건조 과립 및 그의 제조방법
JPH0776584A (ja)	1995-03-20	内皮細胞障害抑制剤
HK40081638A (en)	2023-05-25	Formulation for oral administration of ivermectin and uses thereof